spec sheet7 rows
Pancreatin is a porcine pancreatic extract supplying lipase, amylase and protease, taken with food to replace enzymes a damaged or removed pancreas is not producing.
- Supplies lipase, amylase and protease with every meal
- Straightforwardly effective and not controversial
- Replaces exactly what a damaged pancreas stopped making
- Lipase does the heavy lifting on fat
- Taken with food, so the enzymes arrive with the meal
- Enteric microspheres available for true pancreatic insufficiency
- Pancreatin/pancrelipase is a porcine pancreatic extract containing lipase, protease and amylase; it is enzyme replacement, not a receptor-acting drug [4].
- Until the US FDA's 2010 mandate, pancreatic enzyme products were sold in the USA without new-drug approval; Creon, Zenpep and Pancreaze were the first to be approved on RCT evidence [4].
- Across 22 RCTs, mean change in coefficient of fat absorption ranged from 7.5% (placebo, chronic pancreatitis) to 36% (Creon, chronic pancreatitis), with body-weight gains of 0.1-6.1 kg [1].
- The only head-to-head brand comparison found no significant difference in 72-hour nitrogen absorption between Creon (82.0%) and Zenpep (80.9%) [1].
- Routine acid suppression is not required alongside enzyme replacement; co-prescribed PPI/H2RA did not change end-of-treatment fat absorption in a pooled analysis of 34 trials [2].
Mechanism
The clinically limiting component is lipase, because fat maldigestion is what produces steatorrhoea and weight loss, and lipase is the enzyme most easily destroyed by gastric acid. Preparations are therefore enterically coated to survive the stomach and release at duodenal pH. Dosing is counted in lipase units against fat intake rather than by tablet, and Mezym Forte is a low-strength product compared with the enteric microsphere preparations used for true pancreatic insufficiency and cystic fibrosis.
receptor fingerprint
Dietary triacylglycerol (exogenous pancreatic lipase / colipase activity)Enzymatic hydrolysis to monoglycerides + free fatty acids (replacement, not receptor binding)
Dietary protein (exogenous trypsin/chymotrypsin protease activity)Enzymatic hydrolysis (replacement)
Dietary starch (exogenous alpha-amylase activity)Enzymatic hydrolysis (replacement)
Gastric acid inactivation of lipase (enteric coating / pH-dependent release)Formulation-level protection, not a drug target
Safetyrisks and cautions, not medical advice
Pancreatin is a biological preparation in the gastrointestinal class. A full adverse effect profile has not been compiled for this entry yet, so nothing here should be read as evidence that it is well tolerated; the absence is missing work rather than a finding. What is documented is what the compound is and what it is used for.
Subjective profileweighing the evidence above
Pancreatin is straightforwardly effective and not controversial: it replaces enzymes a damaged pancreas is no longer making, and lipase is the component that decides whether it works, because fat is what goes undigested. The catch is strength rather than safety. Low strength products such as Mezym Forte are aimed at ordinary heaviness after a big meal, while true pancreatic insufficiency and cystic fibrosis need the enteric microsphere preparations at a completely different order of enzyme activity; using the weak one for the serious problem looks like treatment failure when it is really the wrong product.
Where to buy
1 other outlet
Suppliers
Vendors carrying Pancreatin, with live product details and codes. Links are affiliate links that support the wiki at no cost to you.
RUPharma🌐
Pancreatin
PCT.Zone
Pancreatin (Pancrelipase)
Research
- 2010first citedCREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insuffic…
- 2025most recentPancreatic Enzyme Replacement Therapy: Not Only in Chronic Pancreatitis
- 1.Clinical Efficacy and Safety of Treatments for Exocrine Pancreatic Insufficiency: A Systematic Literature Review
- 2.Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON) in patients with pancreatic exocrine insufficiency
- 3.CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency
- 4.Pancrelipase for pancreatic disorders: An update
- 5.Pancreatic Enzyme Replacement Therapy: Not Only in Chronic Pancreatitis
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
Notes and cautions
- There is no boxed warning.
- The signature serious risk is fibrosing colonopathy, a stricturing colopathy reported in children with cystic fibrosis at high lipase doses, which is why dosing is capped at roughly 10,000 lipase units/kg/day; all manufacturers were required by FDA to study this risk [3].
- Common adverse effects are gastrointestinal (abdominal pain, nausea, altered stool) and allergic skin reactions; hyperuricosuria and hyperuricaemia can occur with high doses.
- Because the product is porcine-derived, it carries a theoretical viral-transmission concern and is unacceptable to some patients on religious or dietary grounds, and it is contraindicated in known pork protein hypersensitivity.